Archive: 01/30/2013

In STEMI, diabetes linked to worse long-term outcomes

(HealthDay)—In patients undergoing primary angioplasty for ST-segment elevation myocardial infarction (STEMI), diabetes is associated with worse long-term outcomes, including mortality, reinfarction, stent ...

Jan 30, 2013
popularity not rated yet | comments 0

Linagliptin: Once again, no proof of added benefit

Linagliptin (trade name Trajenta) has been approved since August 2011 to improve blood glucose control in adults with type 2 diabetes. The assessment of the new dossier according to the German Act on the Reform of the Market ...

Jan 30, 2013
popularity not rated yet | comments 0

Perampanel for epilepsy: No proof of added benefit

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In an early benefit assessment according ...

Jan 30, 2013
popularity not rated yet | comments 0

Added benefit of aclidinium bromide is not proven

The drug aclidinium bromide (trade names Eklira, Bretaris) has been approved since October 2012 for widening the narrowed airways of adults with chronic-obstructive pulmonary disease (COPD). The German Institute for Quality ...

Jan 30, 2013
popularity not rated yet | comments 0

New target to stop cancer's spread discovered

Disrupting a key interaction between two types of proteins in cells inhibits the spread of cancerous cells, providing researchers with a new pathway toward developing cancer-fighting drugs, according to new findings by Georgia ...

Jan 30, 2013
popularity not rated yet | comments 0 | with audio podcast